What is the 13F Pro Quality Score for EOLS?

13F Pro ranks Evolus, Inc. (EOLS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View EOLS's current score at https://13fpro.ai/company/EOLS (free sign-up required for the full ranking).

Which hedge funds own the most EOLS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of EOLS include Nantahala Capital Management,, BlackRock,, BRAIDWELL. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/EOLS as soon as new 13F filings post.

Where does 13F Pro source EOLS data?

All Evolus, Inc. fundamentals and ownership data come directly from SEC EDGAR. Evolus, Inc. files with the SEC under CIK 1570562. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is EOLS in?

Evolus, Inc. (EOLS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is EOLS research updated on 13F Pro?

EOLS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Evolus, Inc.(EOLS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1570562 EOLS stock profile & AI dashboard →

13F Pro Quality Score

39.0/100

Rank #2,167 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

77.7/100

Profitability

25.7/100

Balance Sheet

13.7/100

Earnings Quality

35.2/100

Free Cash Flow

19.7/100

Institutional Flow

65.6/100

Revenue Scale

30.2/100

Dilution Risk

20.6/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why EOLS Scores 39/100

exact factor attribution · 2026-09-11

EOLS's composite is driven by revenue growth, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+5.5 pts

78th pct

Institutional flow

+0.8 pts

66th pct

Earnings growth

+0.4 pts

58th pct

Shareholder dilution

-1.5 pts

21th pct

Earnings quality

-1.5 pts

35th pct

Scale

-3.0 pts

30th pct

Capital efficiency

-3.6 pts

14th pct

Profitability

-3.6 pts

26th pct

Free cash flow

-4.5 pts

20th pct

Latest change (2026-08-05): 30 → 31 · ↑ Profit margin 17→28; ↑ Free cash flow 13→24; despite ↓ Revenue growth 80→59

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

EOLS Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Evolus, Inc. (EOLS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EOLS at 39.0/100 on a 32-signal composite quality model, placing it at rank #2,167 of 2,962 stocks — the bottom half of the AI-ranked universe. EOLS scores in the top quartile across revenue growth (77.7). Areas of concern include balance sheet strength (13.7) and free cash flow (19.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 20.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Evolus, Inc. reports quarterly revenue of $84.1M, net income of $-8.1M, an operating margin of -5.4%. Top institutional holders of EOLS by reported 13-F value include Nantahala Capital Management, BlackRock, BRAIDWELL, based on the most recent SEC filings. EOLS trades on the Nasdaq exchange and files with the SEC under CIK 1570562. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EOLS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Evolus, Inc. directly from SEC EDGAR. Evolus, Inc.'s 13F Pro composite quality score has ranged between 26 and 39 since 2021, currently 39.0 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about Evolus, Inc.

Quirks, history, and lore behind EOLS — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty pharmaceutical company · listed on Nasdaq · focused on the medical aesthetics market · headquartered in Southern California.
2
The Numbers
A small-cap company with annual revenue in the low hundreds of millions of dollars, still working toward consistent profitability as it builds out its commercial infrastructure.
3
The History
Founded in 2012 with a singular mission: take on the entrenched giant of the neurotoxin injection market and carve out a meaningful slice of a multi-billion-dollar aesthetic category.
4
The Secret
Its core product is a botulinum toxin type A — the same class of injectable as its dominant rival — but it's positioned as a performance neurotoxin aimed squarely at aesthetic injectors who want an alternative.
5
The Lore
The company licenses its technology from Daewoong Pharmaceutical in South Korea, which touched off a high-profile legal battle with Medytox and Allergan over alleged trade-secret theft.
6
The Giveaway
Its injectable neurotoxin brand Jeuveau — nicknamed #NEWTOX — is the only FDA-approved botulinum toxin launched in the U.S. in nearly a decade when it hit the market in 2019.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$84.1M

Net Income

Q2 2026

$-8.1M

Free Cash Flow

Q2 2026

$-3.6M

Operating Margin

Q2 2026

-5.4%

ROIC

Q2 2026

-14.4%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+11.6% YoY

$297.2MFY 2025

FY22 $148.6MFY23 $202.1MFY24 $266.3MFY25 $297.2M

Net Income

-2.4% YoY

$-51.6MFY 2025

FY22 $-74.4MFY23 $-61.7MFY24 $-50.4MFY25 $-51.6M

Operating Income

+5.1% YoY

$-32.7MFY 2025

FY22 $-65.3MFY23 $-49.2MFY24 $-34.4MFY25 $-32.7M

EPS (Diluted)

+1.2% YoY

$-0.80FY 2025

FY22 $-1.33FY23 $-1.08FY24 $-0.81FY25 $-0.80

Total Assets

-2.9% YoY

$225.9MFY 2025

FY22 $178.0MFY23 $189.0MFY24 $232.6MFY25 $225.9M

Total Debt

+20.2% YoY

$146.1MFY 2025

FY22 $71.9MFY23 $120.4MFY24 $121.5MFY25 $146.1M

Op. Cash Flow

-134.8% YoY

$-42.3MFY 2025

FY22 $-84.9MFY23 $-34.0MFY24 $-18.0MFY25 $-42.3M

Free Cash Flow

-134.7% YoY

$-45.7MFY 2025

FY22 $-86.5MFY23 $-34.5MFY24 $-19.5MFY25 $-45.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$297.2M +11.6%	$266.3M +31.8%	$202.1M +36.0%	$148.6M +49.1%	$99.7M +76.3%	$56.5M
Net Income	$-51.6M -2.4%	$-50.4M +18.3%	$-61.7M +17.1%	$-74.4M -59.0%	$-46.8M +71.3%	$-163.0M
Operating Income	$-32.7M +5.1%	$-34.4M +30.1%	$-49.2M +24.6%	$-65.3M -47.1%	$-44.4M +71.0%	$-153.1M
EPS (Diluted)	$-0.80 +1.2%	$-0.81 +25.0%	$-1.08 +18.8%	$-1.33 -41.5%	$-0.94 +80.5%	$-4.83
Total Assets	$225.9M -2.9%	$232.6M +23.1%	$189.0M +6.2%	$178.0M -30.9%	$257.5M +23.2%	$209.1M
Total Debt	$146.1M +20.2%	$121.5M +1.0%	$120.4M +67.4%	$71.9M +0.9%	$71.2M	—
Operating Cash Flow	$-42.3M -134.8%	$-18.0M +47.1%	$-34.0M +59.9%	$-84.9M -154.3%	$-33.4M +42.3%	$-57.9M
Free Cash Flow	$-45.7M -134.7%	$-19.5M +43.5%	$-34.5M +60.2%	$-86.5M -156.1%	$-33.8M +42.4%	$-58.7M

Get alerted when EOLS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Evolus, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of EOLS

Nantahala Capital Management, LLC
$38.9M5,602,021 sh
BlackRock, Inc.
$33.6M4,840,828 sh
BRAIDWELL LP
$21.9M3,155,209 sh
Frazier Life Sciences Management, L.P.
$18.3M2,630,665 sh
PERCEPTIVE ADVISORS LLC
$17.1M2,459,285 sh
VANGUARD CAPITAL MANAGEMENT LLC
$16.4M2,362,893 sh
MILLENNIUM MANAGEMENT LLC
$12.4M1,787,929 sh
STATE STREET CORP
$11.8M1,697,294 sh
GEODE CAPITAL MANAGEMENT, LLC
$11.2M1,608,394 sh
Stonepine Capital Management, LLC
$11.0M1,590,162 sh

Fund	Value	Shares
Nantahala Capital Management, LLC	$38.9M	5,602,021
BlackRock, Inc.	$33.6M	4,840,828
BRAIDWELL LP	$21.9M	3,155,209
Frazier Life Sciences Management, L.P.	$18.3M	2,630,665
PERCEPTIVE ADVISORS LLC	$17.1M	2,459,285
VANGUARD CAPITAL MANAGEMENT LLC	$16.4M	2,362,893
MILLENNIUM MANAGEMENT LLC	$12.4M	1,787,929
STATE STREET CORP	$11.8M	1,697,294
GEODE CAPITAL MANAGEMENT, LLC	$11.2M	1,608,394
Stonepine Capital Management, LLC	$11.0M	1,590,162

Companies Similar to EOLS

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ARDX

ARDELYX, INC.

AI score

Very similar · 8 shared holders

DIADEMA PARTNERS LP Krensavage Asset Management, LLC Stonepine Capital Management, LLC

SUPN

SUPERNUS PHARMACEUTICALS, INC.

AI score

Similar quality profile · 9 shared holders

ARMISTICE CAPITAL, LLC RICE HALL JAMES & ASSOCIATES, LLC Soleus Capital Management, L.P.

KIDS

ORTHOPEDIATRICS CORP

AI score

Similar quality profile · 5 shared holders

BRAIDWELL LP Soleus Capital Management, L.P.Nantahala Capital Management, LLC

MNKD

MANNKIND CORP

AI score

Similar quality profile · 8 shared holders

Frazier Life Sciences Management, L.P.BRAIDWELL LP Stonepine Capital Management, LLC

MGNX

MACROGENICS INC

AI score

Similar quality profile · 5 shared holders

ARMISTICE CAPITAL, LLC DIADEMA PARTNERS LP PINNACLE ASSOCIATES LTD

VNDA

Vanda Pharmaceuticals Inc.

AI score

Similar quality profile · 4 shared holders

Krensavage Asset Management, LLC FULLER & THALER ASSET MANAGEMENT, INC.China Universal Asset Management Co., Ltd.

PHAT

Phathom Pharmaceuticals, Inc.

AI score

Similar quality profile · 8 shared holders

Frazier Life Sciences Management, L.P.PERCEPTIVE ADVISORS LLC DIADEMA PARTNERS LP

IMCR

Immunocore Holdings plc

AI score

Similar quality profile · 7 shared holders

BRAIDWELL LP Frazier Life Sciences Management, L.P.ARMISTICE CAPITAL, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put EOLS on your watchlist

Track score changes the day Evolus, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is EOLS a good stock to buy?

13F Pro's AI-powered analysis of Evolus, Inc. (EOLS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EOLS are available on the EOLS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. EOLS is classified as a small company.

Which hedge funds own EOLS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EOLS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Evolus, Inc.'s investment landscape.